

<http://www.agilent.com/about/newsroom/presrel/2015/04may-gp15010.html>

Agilent to Acquire Cartagenia, Leading Provider of Software to Enable Clinical Analysis of Genomics Data

SANTA CLARA, Calif., and BOSTON, May 4, 2015

Agilent Technologies Inc. (NYSE: A) and Cartagenia today announced that they have signed a definitive agreement under which Agilent will acquire Cartagenia, a leading provider of software and services for clinical genetics and molecular pathology labs.

Cartagenia, which has offices in Leuven, Belgium, and Boston, Massachusetts, provides software solutions for variant assessment and reporting of clinical genomics data from next-generation sequencing and microarrays. Uniquely geared to routine clinical labs, Cartagenia's solutions are FDA-registered as exempt Class I Medical Devices in the U.S. and as Class I Medical Devices in Europe. The Cartagenia Bench platform enables technicians, lab directors and clinicians to visualize, assess and report clinical genetics data in the context of patient information.

With Cartagenia Bench, labs can build an internal knowledge base, build variant assessment SOPs, automate report drafting, and access a wide range of community-validated, private and premium content resources, whether for oncology or inherited disease.

Cartagenia's platform also provides deep support for consortia of collaborating labs. Data-sharing has become an essential requirement for the community, and through private and public consortia, users can connect and pool their knowledge on rare diseases and actionable findings.

"Cartagenia's approach to enabling the interpretation of clinical genomics data is revolutionary," said Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group. "We look forward to providing Cartagenia's software solutions to our clinical genetics and molecular oncology customers and to providing Cartagenia's existing customers with access to our global service and support network. Together, Agilent and Cartagenia can help remove bottlenecks inherent in analysis, interpretation and reporting clinical data-resulting in faster answers for patients."

"Joining forces with Agilent is an excellent strategic fit and provides tremendous opportunity both for our customers-who will benefit from integration with a broad family of solutions and a range of new applications-and for our team, as we'll be able to further accelerate our success and growth through Agilent's global reach and leading footprint in clinical labs," said Herman Verrelst, chief executive officer, Cartagenia.

The acquisition is expected to be completed May 19, subject to local laws and regulations and customary closing conditions. Cartagenia employs 36 people, all of whom will be offered employment with Agilent.

Financial terms of the transaction were not disclosed.

About Cartagenia

Cartagenia supplies variant assessment support and lab report automation software, database systems, and related services to genetic labs, pathology labs and clinicians, enabling them to perform clinically relevant genetic analyses quickly and efficiently, and offer patients and carers high-quality genetic interpretation and counseling.

Cartagenia Bench Lab allows automation of variant assessment protocols and lab report generation for structural and molecular variant assays such as Arrays, Sanger and Next Generation Sequencing. It supports communication with referring physicians, allows labs and clinicians to put variants in their clinical context, and supports confident data sharing.

The Cartagenia Bench platform is built in collaboration with genetics labs and clinical experts involved in routine medical practice. Because of this, Bench Lab addresses the specific needs of genetic diagnostic labs and clinicians.

Cartagenia Bench is built using a certified ISO13485 Quality Management System and is registered with the FDA as an exempt Class I Medical Device in the United States and as a Class I Medical Device in Europe in conformity with the essential requirements and provisions of the Council Directive 93/42/EEC concerning medical devices, and with the relevant harmonized standards EN ISO62304.

For more information, visit www.cartagenia.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. Agilent generated revenues of \$4.0 billion in fiscal 2014. The company employs about 12,000 people worldwide. Information about Agilent is available at www.agilent.com.

###

Contact:

Michele Drake, Agilent corporate
+1 408 345 8396
michele_drake@agilent.com


Victoria Wadsworth-Hansen, Agilent business
+45 2933 6980
victoria.wadsworth-hansen@agilent.com

Imke Debecker, Cartagenia
imke.debecker@cartagenia.com

Investor Contact:

Alicia Rodriguez, Agilent
+1 408 345 8948
alicia_rodriguez@agilent.com

<http://www.agilent.com/about/newsroom/presrel/2015/04may-gp15010.html>



Agilent Technologies to Acquire Cartagenia, Leading Provider of Software to Enable Clinical Analysis of Genomics Data

May 04, 2015 11:00 AM Eastern Daylight Time

SANTA CLARA, Calif. & BOSTON--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE:A) and Cartagenia today announced that they have signed a definitive agreement under which Agilent will acquire Cartagenia, a leading provider of software and services for clinical genetics and molecular pathology labs.

Cartagenia, which has offices in Leuven, Belgium, and Boston, Massachusetts, provides software solutions for variant assessment and reporting of clinical genomics data from next-generation sequencing and microarrays. Uniquely geared to routine clinical labs, Cartagenia's solutions are FDA-registered as exempt Class I Medical Devices in the U.S. and as Class I Medical Devices in Europe. The Cartagenia Bench platform enables technicians, lab directors and clinicians to visualize, assess and report clinical genetics data in the context of patient information.

With Cartagenia Bench, labs can build an internal knowledge base, build variant assessment SOPs, automate report drafting, and access a wide range of community-validated, private and premium content resources, whether for oncology or inherited disease.

Cartagenia's platform also provides deep support for consortia of collaborating labs. Data-sharing has become an essential requirement for the community, and through private and public consortia, users can connect and pool their knowledge on rare diseases and actionable findings.

"Cartagenia's approach to enabling the interpretation of clinical genomics data is revolutionary," said Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group. "We look forward to providing Cartagenia's software solutions to our clinical genetics and molecular oncology customers and to providing Cartagenia's existing customers with access to our global service and support network. Together, Agilent and Cartagenia can help remove bottlenecks inherent in analysis, interpretation and reporting clinical data—resulting in faster answers for patients."

"Joining forces with Agilent is an excellent strategic fit and provides tremendous opportunity both for our customers—who will benefit from integration with a broad family of solutions and a range of new applications—and for our team, as we'll be able to further accelerate our success and growth through Agilent's global reach and leading footprint in clinical labs," said Herman Verrelst, chief executive officer, Cartagenia.

The acquisition is expected to be completed May 19, subject to local laws and regulations and customary closing conditions. Cartagenia employs 36 people, all of whom will be offered employment with Agilent.

Financial terms of the transaction were not disclosed.

About Cartagenia

Cartagenia supplies variant assessment support and lab report automation software, database systems, and related services to genetic labs, pathology labs and clinicians, enabling them to perform clinically relevant genetic analyses quickly and efficiently, and offer patients and carers high-quality genetic interpretation and counseling.

Cartagenia Bench Lab allows automation of variant assessment protocols and lab report generation for structural and molecular variant assays such as Arrays, Sanger and Next Generation Sequencing. It supports communication with referring physicians, allows labs and clinicians to put variants in their clinical context, and supports confident data sharing.

The Cartagenia Bench platform is built in collaboration with genetics labs and clinical experts involved in routine medical practice. Because of this, Bench Lab addresses the specific needs of genetic diagnostic labs and clinicians.

Cartagenia Bench is built using a certified ISO13485 Quality Management System and is registered with the FDA as an exempt

Class I Medical Device in the United States and as a Class I Medical Device in Europe in conformity with the essential requirements and provisions of the Council Directive 93/42/EEC concerning medical devices, and with the relevant harmonized standards EN ISO62304.

For more information, visit www.cartagenia.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. Agilent generated revenues of \$4.0 billion in fiscal 2014. The company employs about 12,000 people worldwide. Information about Agilent is available at www.agilent.com.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.

Contacts

EDITORIAL CONTACTS:

Agilent Corporate

Michele Drake, +1 408-345-8396

michele_drake@agilent.com

or

Agilent Business

Victoria Wadsworth-Hansen, +45 2933 6980

victoria.wadsworth-hansen@agilent.com

or

Cartagenia

Imke Debecker

imke.debecker@cartagenia.com

or

INVESTOR CONTACT:

Agilent

Alicia Rodriguez, +1 408-345-8948

alicia_rodriguez@agilent.com



Agilent to Buy Cartagenia

May 04, 2015 | [a GenomeWeb staff reporter](#)

NEW YORK(GenomeWeb) – Agilent Technologies and Cartagenia said today that Agilent will acquire Cartagenia for an undisclosed sum.

The acquisition will provide Agilent with software solutions for its clinical genetics and molecular oncology customers, while providing stronger support and services for Cartagenia's clients, Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group, said in a statement.

The acquisition is expected to be completed by May 19, subject to local laws and regulations and customary closing conditions, the companies said. As part of the deal, all 36 Cartagenia employees will be offered employment with Agilent, the firms said.

From its offices in Leuven, Belgium, and Boston, Cartagenia provides a suite of software solutions and services based on its Bench Lab platform for assessing, reporting, and sharing information on genomic variants from next-generation sequencing and microarray data in clinical contexts. The company's solutions are FDA-registered as exempt Class I Medical Devices in theUSand as Class I Medical Devices in Europe.

"Joining forces with Agilent is an excellent strategic fit and provides tremendous opportunity both for our customers ... and for our team," Herman Verrelst, Cartagenia's CEO, said in a statement.

He added that Cartagenia's customers will benefit from the integration of the firm's products with a broad family of solutions and a range of new applications.

News

2014
30
May

Cartagenia and Agilent Technologies Announce Global Distribution Agreement for CNV Analysis

To assist Cytogenetic Labs in the Clinical Interpretation of Microarray Data.

SANTA CLARA, Calif., May, 2014—Agilent Technologies, Inc. (NYSE: A) today announced an agreement for global distribution of Cartagenia's cloud-based software for copy number variation (CNV) analysis. This agreement will enable Agilent to sell annual licenses for Cartagenia's Bench Lab™ CNV module to small and medium-sized cytogenetic laboratories. Now, labs with limited budget and little or no bioinformatics resources are able to gain access to a powerful interpretation support module to draft clinical grade reports.

"Cartagenia is pleased to work with Agilent on this distribution agreement of our Bench Lab CNV module," said Herman Verrelst, chief executive officer for Cartagenia. "Patient-centric interpretation of microarray data can be greatly facilitated by adopting automated data analysis pipelines and workflows, increasing lab efficiency. Through Agilent's network we can now reach small to medium-size labs more efficiently and provide them with our data analysis platform. The CNV module is a proven platform, offers standardized workflows, and automated SOPs for fast turnaround times. And, since it is a cloud-based platform, it allows for rapid installation, integration with legacy data, and provides labs with greater access to our product without adding bioinformatics resources."

Cartagenia supplies interpretation support software, database systems, and related services to genetic labs and clinicians, enabling them to perform clinically relevant analysis of genetic findings quickly and efficiently.

The Cartagenia Bench CNV platform is built in collaboration with genetics labs and clinical experts involved in routine medical practice. Because of this, Bench Lab CNV addresses the specific needs of genetic diagnostic labs and clinicians.

"Agilent is the first worldwide reseller to offer the Cartagenia Bench Lab CNV module, and we are excited to provide this solution to our cytogenetic customers," said Jacob Thayson, Agilent's vice president and general manager, Diagnostics and Genomics Group. "Labs with minimal software budget and resources can now afford to implement proven, standardized processes to analyze, interpret, and report their CGH data and generate precise draft lab reports with minimal disruption to their analysis workflow and staff."

To learn more, please visit: www.agilent.com/genomics/cartagenia (<http://www.agilent.com/genomics/cartagenia>).

About Cartagenia

Cartagenia Bench Lab™ CNV is built using a certified ISO13485 Quality Management System and is registered with the FDA as an exempt Class I Medical Device in the United States and as a Class I Medical Device in Europe in conformity with the essential requirements and provisions of the Council Directive 93/42/EEC concerning medical devices, and with the relevant harmonized standards EN ISO62304. www.cartagenia.com

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,600 employees serve customers in more than 100 countries. Agilent had revenues of \$6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com (<http://www.agilent.com>).

On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.

###

GET IN TOUCH WITH US

 **Press contact**

press@cartagenia.com (<mailto:press@cartagenia.com>)

Market Update (NYSE:A): Agilent Technologies to Acquire Cartagenia, Leading Provider of Software to Enable Clinical Analysis of Genomics Data

By Heather Cunnings, on May 4th, 2015, 11:00 am in [Healthcare](#)



[Business Wire] – Agilent Technologies Inc. and Cartagenia today announced that they have signed a definitive agreement under which Agilent will acquire Cartagenia, a leading provider of software and services for clinical genetics and molecular pathology labs.

[Read more on this.](#)

Agilent Technologies Inc. (A), with a current market cap of \$14.06B, opened this morning at \$41.88.

Shares have traded today between \$41.70 and \$41.98 per share with a one year range of \$35.62 to \$43.59.

Agilent (A) shares are currently priced at 24.75x this year's forecasted earnings, which makes them relatively expensive compared to the industry's 24.67x earnings multiple for the same period.

And for those looking to make a return holding the stock, the company pays shareholders \$0.40 per share annually in dividends, yielding 0.90%.

In a review of the consensus earnings estimate this quarter, 16 sell-side analysts are looking at \$0.39 per share, which would be \$0.33 worse than the year-ago quarter and a \$0.00 sequential decrease. The full-year EPS estimate is \$1.69, which would be a \$1.35 better than last year.

The quarterly earnings estimate is predicated on a consensus revenue forecast of \$989.30 Million. If reported, that would be a 42.82% decrease over the year-ago quarter.

More recently, UBS Initiated A at Neutral (Mar 10, 2015). Previously, Robert W. Baird downgraded A from Outperform to Neutral.

Given all the information above, we should disclose to readers that the average price target is \$45.21, which is 7.95% above than it opened this morning.

Summary (NYSE:A): Agilent Technologies, Inc. provides bio-analytical solutions and services to the life sciences, diagnostics and genomics, chemical analysis, communications, and electronics industries worldwide. The company's Life Sciences and Diagnostics segment offers liquid chromatography systems, columns, and components; liquid chromatography mass spectrometry systems; laboratory software and informatics systems; laboratory automation and robotic systems; dissolution testing; nucleic acid solutions; nuclear magnetic resonance, magnetic resonance imaging, and X-ray diffraction systems; immunohistochemistry; in situ hybridization; hematoxylin and eosin staining; special staining, DNA mutation detection; genotyping; gene copy number determination; identification of gene rearrangements; DNA methylation and gene expression profiling; next generation sequencing target enrichment; and automated gel electrophoresis-based sample analysis systems. Its Chemical Analysis segment provides gas chromatography systems, columns, and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; inductively coupled plasma optical emission spectrometry instruments; molecular spectroscopy instruments; software and data systems; and vacuum pumps and measurement technologies. Agilent Technologies, Inc. sells its products through direct sales; and distributors, resellers, manufacturer's representatives, telesales, and electronic commerce. The company was founded in 1999 and is headquartered in Santa Clara, California.

More on this topic ([What's this?](#))

[Faster Than the Data Curve: Accelerating the Network](#) (Telecom Ramblings, 4/10/15)

[Cyan Lands INDATEL, Regional Carriers for 100G, SDN](#) (Telecom Ramblings, 4/13/15)

[Let's Dockerize VoIP](#) (Telecom Ramblings, 3/6/15)

Read more on [Agilent Technologies](#), [Computer Software](#) at [Wikinvest](#)

Press Release | Thu May 29, 2014 6:00pm EDT

TRADE NEWS: Agilent Technologies Announces Global Distribution Agreement with Cartagenia for CNV Analysis

* Reuters is not responsible for the content in this press release.

-
-
-
-
-
-

TRADE NEWS: Agilent Technologies Announces Global Distribution Agreement with Cartagenia for CNV Analysis

To Assist Cytogenetic Labs in the Clinical Interpretation of Microarray Data

Agilent Technologies Inc. (NYSE: A) today announced an agreement for global distribution of Cartagenia's cloud-based software for copy number variation (CNV) analysis. This agreement will enable Agilent to sell usage-priced annual licenses for Cartagenia's Bench Lab CNV module to small and medium-sized cytogenetic laboratories. The use-based licenses allow labs with limited budgets and little or no bioinformatics resources to gain access to a powerful interpretation support module to draft clinical grade reports.

"Cartagenia is pleased to work with Agilent on this distribution agreement of our Bench Lab CNV module," said Herman Verrelst, chief executive officer, Cartagenia. "Patient-centric interpretation of microarray data can be greatly facilitated by adopting automated data analysis pipelines and workflows, increasing lab efficiency."

"With expanded distribution capabilities, we can now reach small- to medium-sized labs more efficiently and provide them with our data analysis platform," Verrelst added. "The CNV module is a proven platform, offers standardized workflows, and automated SOPs for fast turnaround times. Since it is a cloud-based platform, it allows for rapid installation, integration with legacy data, and provides labs with greater access to our product without adding bioinformatics resources."

Cartagenia supplies interpretation support software, database systems and related services to genetic labs and clinicians, enabling them to perform clinically relevant analysis of genetic findings quickly and efficiently.

The Cartagenia Bench CNV platform is built in collaboration with genetics labs and clinical experts involved in routine medical practice. Because of this, Bench Lab CNV addresses the specific needs of genetic diagnostic labs and clinicians.

“Agilent is the first worldwide reseller to offer the Cartagenia Bench Lab CNV, and we are excited to provide this solution,” said Jacob Thaysen, Agilent’s vice president and general manager, Diagnostics and Genomics Group. “Labs with minimal software budget and resources can now afford to implement proven, standardized processes to analyze, interpret, and report their CGH data and generate precise draft lab reports with minimal disruption to their analysis workflow and staff.”

To learn more, please visit www.agilent.com/genomics/cartagenia.

About Cartagenia

Cartagenia Bench Lab CNV is built using a certified ISO13485 Quality Management System and is registered with the FDA as an exempt Class I Medical Device in the United States and as a Class I Medical Device in Europe in conformity with the essential requirements and provisions of the Council Directive 93/42/EEC concerning medical devices, and with the relevant harmonized standards EN ISO62304. www.cartagenia.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,600 employees serve customers in more than 100 countries. Agilent had revenues of \$6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com.

On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.

Agilent Cytogenomics software is For Research Use Only. Not for use in diagnostic procedures.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.

Agilent Technologies Inc.
Susan Berg, +1 408-553-7093
susan_berg1@agilent.com



Cartagenia and Agilent Technologies announce distribution agreement for Bench Lab CNV - goo.gl/3Xt5kP

 Vertaling weergeven



07.07 - 6 jun. 2014

Press Release

May 4, 2015 15:00 UTC

Agilent Technologies to Acquire Cartagenia, Leading Provider of Software to Enable Clinical Analysis of Genomics Data

¹ SANTA CLARA, Calif. & BOSTON--(Business Wire)--Agilent Technologies Inc. (NYSE:A) and Cartagenia today announced that they have signed a definitive agreement under which Agilent will acquire Cartagenia, a leading provider of software and services for clinical genetics and molecular pathology labs.

Cartagenia, which has offices in Leuven, Belgium, and Boston, Massachusetts, provides software solutions for variant assessment and reporting of clinical genomics data from next-generation sequencing and microarrays. Uniquely geared to routine clinical labs, Cartagenia's solutions are FDA-registered as exempt Class I Medical Devices in the U.S. and as Class I Medical Devices in Europe. The Cartagenia Bench platform enables technicians, lab directors and clinicians to visualize, assess and report clinical genetics data in the context of patient information.

With Cartagenia Bench, labs can build an internal knowledge base, build variant assessment SOPs, automate report drafting, and access a wide range of community-validated, private and premium content resources, whether for oncology or inherited disease.

Cartagenia's platform also provides deep support for consortia of collaborating labs. Data-sharing has become an essential requirement for the community, and through private and public consortia, users can connect and pool their knowledge on rare diseases and actionable findings.

"Cartagenia's approach to enabling the interpretation of clinical genomics data is revolutionary," said Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group. "We look forward to providing Cartagenia's software solutions to our clinical genetics and molecular oncology customers and to providing Cartagenia's existing customers with access to our global service and support network. Together, Agilent and Cartagenia can help remove bottlenecks inherent in analysis, interpretation and reporting clinical data—resulting in faster answers for patients."

"Joining forces with Agilent is an excellent strategic fit and provides tremendous opportunity both for our customers—who will benefit from integration with a broad family of solutions and a range of new applications—and for our team, as we'll be able to further accelerate our success and growth through Agilent's global reach and leading footprint in clinical labs," said Herman Verrelst, chief executive officer, Cartagenia.

The acquisition is expected to be completed May 19, subject to local laws and regulations and customary closing conditions. Cartagenia employs 36 people, all of whom will be offered employment with Agilent.

Financial terms of the transaction were not disclosed.

About Cartagenia

Cartagenia supplies variant assessment support and lab report automation software, database systems, and related services to genetic labs, pathology labs and clinicians, enabling them to perform clinically relevant genetic analyses quickly and efficiently, and offer patients and carers high-quality genetic interpretation and counseling.

Cartagenia Bench Lab allows automation of variant assessment protocols and lab report generation for structural and molecular variant assays such as Arrays, Sanger and Next Generation Sequencing. It supports communication with referring physicians, allows labs and clinicians to put variants in their clinical context, and supports confident data sharing.

The Cartagenia Bench platform is built in collaboration with genetics labs and clinical experts involved in routine medical practice. Because of this, Bench Lab addresses the specific needs of genetic diagnostic labs and clinicians.

Cartagenia Bench is built using a certified ISO13485 Quality Management System and is registered with the FDA as an exempt Class I Medical Device in the United States and as a Class I Medical Device in Europe in conformity with the essential requirements and provisions of the Council Directive 93/42/EEC concerning medical devices, and with the relevant harmonized standards EN ISO62304.

For more information, visit www.cartagenia.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. Agilent generated revenues of \$4.0 billion in fiscal 2014. The company employs about 12,000 people worldwide. Information about Agilent is available at www.agilent.com.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.

EDITORIAL CONTACTS:

Agilent Corporate
Michele Drake, +1 408-345-8396
michele_drake@agilent.com

or

Agilent Business

Victoria Wadsworth-Hansen, +45 2933 6980
victoria.wadsworth-hansen@agilent.com

or

Cartagenia

Imke Debecker

imke.debecker@cartagenia.com

or

INVESTOR CONTACT:

Agilent

Alicia Rodriguez, +1 408-345-8948

alicia_rodriguez@agilent.com

Read more: <http://www.digitaljournal.com/pr/2542139#ixzz3Zpmo4CPP>